The non-exclusive agreement provides Merck Millipore the opportunity to continue to develop and ultimately commercialize iPS cells for research applications. Under the agreement, Merck Millipore will continue to offer its STEMCCA™ reprogramming kits, which provide a highly efficient, reproducible method for creating iPS cells.
Merck Millipore press release, September 17, 2012
Merck Millipore concludes license agreement to use the iPS cell patent portfolio of iPS Academia, Kyoto